A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 14, 2022

Primary Completion Date

August 21, 2022

Study Completion Date

August 21, 2022

Conditions
Severe Hemophilia A
Interventions
DRUG

FRSW117

"Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117."

Trial Locations (5)

214100

Affiliated Hospital of Jiangnan University, Wuxi

266000

The Affiliated Hospital of Qingdao University, Qingdao

276800

People'S Hospital of Rizhao, Rizhao

300020

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin

450000

People'S Hospital of Zhengzhou, Zhengzhou

All Listed Sponsors
lead

Jiangsu Gensciences lnc.

INDUSTRY

NCT05265286 - A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | Biotech Hunter | Biotech Hunter